SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
January 26, 2023
 · 
14 min read
Pharm Country
TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferencePresentation scheduled for Monday, January 9, 2023 at 9:45 AM PT
January 6, 2023
 · 
1 min read
FDA
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
December 28, 2022
 · 
19 min read
Business
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 10, 2022
 · 
9 min read
Pharm Country
TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business UpdateConference call to be held Thursday, November 10, 2022 at 8:30 AM ET
November 8, 2022
 · 
1 min read
Drug Development
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
October 26, 2022
 · 
7 min read
Drug Development
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
October 13, 2022
 · 
8 min read
Pharm Country
TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 9, 2022
 · 
1 min read
Senior Female Scientist Works with High Tech Equipment in a Modern Laboratory. Her Colleagues are Working Beside Her.
Drug Development
Clinical Catch-Up: 89bio, Tonix, Arcutis and More
August 28, 2022
 · 
4 min read
 · 
Mark Terry
Drug Development
NEJM Publishes Data Touting Efficacy of TG Therapeutics’ MS Drug
August 26, 2022
 · 
3 min read
 · 
Alex Keown
Drug Development
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
August 25, 2022
 · 
11 min read
Business
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsConference call to be held today, August 8, 2022 at 8:30 AM ET
August 8, 2022
 · 
9 min read
Business
TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business UpdateConference call to be held Monday, August 8, 2022 at 8:30 AM ET
August 5, 2022
 · 
1 min read
Drug Development
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
June 27, 2022
 · 
7 min read
Sarah Silbiger/Getty Images
Drug Development
FDA Action Alert: BMS, TG, Spero and Merck
June 17, 2022
 · 
3 min read
 · 
Mark Terry
Pharm Country
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
June 3, 2022
 · 
7 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS